The value of clinical AI in community oncology

The challenges: Growing population of new diagnoses and survivors

With a growing population of new diagnoses and survivors, community oncology providers face significant challenges that impact the delivery of care.

By 2023

- 2.3 million newly diagnosed cancer patients
- 22.2 million survivors

By 2030

- 22.2 million survivors

Value-based care requirements

Cardinal Health, as the exclusive reseller of Jvion oncology products to community oncology practices, aims to provide higher-quality, more highly coordinated care for this growing population.

90%

90% of providers believe there is a need for AI to identify high-risk patients.

81%

81% of providers believe that AI can improve patient outcomes.

68%

68% of providers believe that AI will reduce costs.

35

35 percent of new models are value-based.

Social determinants of health

Risk factors such as financial, social, and behavioral determinants of health significantly impact patients’ health outcomes. Addressing these factors will help to ensure that patients receive the care they need when they need it, such as hospice.

90%

90% of providers believe that social determinants of health impact their patients.

How clinical AI can address these challenges:

With the use of clinical AI, providers can:

- Identify high-risk patients
- Improve patient outcomes
- Reduce costs

Jvion CORE™ — an AI platform that helps oncology care teams:

- Identify patients at risk for depression
- Projects patients’ propensities for depression over the next 6 months
- Underscores patients at risk for poorly controlled pain
- Predicts the likelihood of functional decline
- Pre-emptively deters patients who are likely to miss an appointment
- Identifies patients who would benefit most from early hospice/palliative care at end of life
- Increases in palliative care, hospice, and access to core cancer services

Jvion’s ability to help NWMS providers answer questions such as, ‘Should we proceed with hospice care for this patient?’ has been critical to NWMS’ delivery of the comprehensive care solutions that patients need when they need them, such as hospice.

The value of Jvion CORE™ in community oncology

The Jvion CORE™ “A” key to improving the value equation

Community-based oncology practices have seen tremendous improvement in patient care through the use of clinical AI.

“Jvion’s ability to help providers get the most out of fewer resources has been tremendous. Benefits have been realized by the entire practice — from an administrative standpoint, it’s сделало the entire practice much more efficient.”

Chief Executive Officer of The Center for Cancer and Blood Disorders – Barry Russo, M.D.

“Jvion’s ability to help providers get the most out of fewer resources has been tremendous. Benefits have been realized by the entire practice — from an administrative standpoint, it’s сделало the entire practice much more efficient.”

Director of Value Based Care, Northwest Medical Specialties – Dave White, M.D.

Reduces 30-day readmission

• Improves end-of-life planning and communication

Up to $3 million

Cardinal Health is the exclusive reseller of Jvion oncology products to community oncology practices.

To request a demo of the Jvion CORE™ Clinical AI technology, go to cardinalhealth.com/jvion.

By 2023

- 2.3 million newly diagnosed cancer patients
- 22.2 million survivors

By 2030

- 22.2 million survivors

Cardinal Health is the exclusive reseller of Jvion oncology products to community oncology practices.

To request a demo of the Jvion CORE™ Clinical AI technology, go to cardinalhealth.com/jvion.